Anima specializes in treating targets long viewed as “undruggable” by targeting cellular mechanisms that regulate mRNA translation of proteins with specific biological roles in coordinating and regulating translation of individual mRNAs and pathways . . .
The post Anima Biotech Heads for the Light with Up-to-$2.4B Takeda Partnership appeared first on GEN – Genetic Engineering and Biotechnology News.
